North America Bladder Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
USD 1,591.09 million |
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
>北美膀胱癌诊断市场，按测试类型（膀胱镜检查、尿液实验室测试、活检、影像学测试等）、分期（第一期、第二期、第三期和第四期）、癌症类型（膀胱移行细胞癌、鳞状细胞膀胱癌和其他癌症类型）、最终用户（医院、诊断影像中心、癌症研究机构、独立诊断实验室和相关实验室）、分销渠道（直接招标和零售销售）划分，行业趋势及预测至 2030 年。
北美膀胱癌诊断市场分析及规模
北美膀胱癌诊断市场本质上是分散的，因为它由许多北美公司组成，例如 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV 和 Bio-Rad Laboratories, Inc. 等。这些公司的存在为整个地区的膀胱癌诊断提供了具有竞争力的价格。由于这些参与者在区域和国际层面的存在，供应商和制造商提供具有不同规格和特性的产品，价格各有不同。膀胱癌患病率的上升推动了市场的增长。此外，人们对膀胱癌早期检测的认识不断提高，预计将推动市场增长。
Data Bridge Market Research 分析，北美膀胱癌诊断市场预计到 2030 年将达到 15.9109 亿美元，预测期内复合年增长率为 9.1%。本市场报告还深入介绍了定价分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
检测类型（膀胱镜检查、尿液实验室检测、活检、影像学检测等）、分期（I 期、II 期、III 期和 IV 期）、癌症类型（膀胱移行细胞癌、膀胱鳞状细胞癌和其他癌症类型）、最终用户（医院、诊断影像中心、癌症研究机构、独立诊断实验室和相关实验室）、分销渠道（直接招标和零售） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV、Bio-Rad Laboratories, Inc.、Agilent Technologies, Inc.、FUJIFILM Corporation、CANON MEDICAL SYSTEMS CORPORATION、Siemens Healthcare GmbH、BD、Illumina, Inc. Neusoft Corporation、Abbott、General Electric Company、Hologic Inc.、QIAGEN、Cepheid、Ambu A/S、Time Medical Holding 和 MinFound Medical Systems Co. 等 |
市场定义
膀胱癌始于膀胱内壁健康细胞（最常见的是尿路上皮细胞）发生变化并失控生长，形成肿块（称为肿瘤）。尿路上皮细胞也位于肾盂、输尿管和尿道内壁。肾盂和输尿管中发生的癌症也被认为是一种尿路上皮癌，通常称为上尿路尿路上皮癌。在大多数情况下，它的治疗方法与本指南中描述的膀胱癌大致相同。肿瘤可以是癌性的，也可以是良性的。癌性肿瘤是恶性的，这意味着它可以生长并扩散到身体的其他部位。良性肿瘤意味着肿瘤可以生长但不会扩散。良性膀胱肿瘤非常罕见。
北美膀胱癌诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
司机
全球膀胱癌发病率上升
大多数与膀胱癌相关的基因突变都是在人的一生中形成的，而不是出生前遗传的。其中一些后天基因突变是由于接触致癌化学物质或辐射而导致的。例如，烟草烟雾中的化学物质可以被吸收到血液中，经肾脏过滤，最终进入尿液，从而影响膀胱细胞。其他化学物质也可能以同样的方式到达膀胱。然而，有时，基因变化可能只是细胞内部发生的随机事件，没有外部原因。
膀胱癌主要发生在老年人身上。约有 90% 的膀胱癌患者年龄超过 55 岁。膀胱癌患者的平均确诊年龄为 73 岁。膀胱癌病例的增加促进了膀胱癌诊断产品的使用，从而推动了膀胱癌诊断市场的增长。
提高对膀胱癌早期诊断的认识
5 月份是美国全国范围内的膀胱癌宣传月。该月旨在将膀胱肿瘤社区聚集在一起，帮助提高认识，并让更多人关注经常被忽视的患者群体。尽管膀胱癌并不像乳腺癌或肺癌那样常见，但对治疗膀胱肿瘤患者的新方法和创新方法的需求从未如此迫切。研究表明，美国有超过 72 万名患者正在与膀胱癌作斗争。
随着当前北美卫生危机在 COVID-19 的影响下不断变化，了解患者护理、教育和癌症研究的影响的重要性变得比以往任何时候都更加明显。展望未来，在为膀胱肿瘤患者发现新的有效药物方面仍有许多基础工作要做，并且迫切需要持续教育人们应对治疗膀胱癌时面临的众多挑战。
膀胱癌宣传月是一项专门致力于这些努力的运动，即使在疫情期间，帮助这一患者群体仍然是重中之重。因此，对膀胱癌早期诊断的认识不断提高，推动了市场的增长。
机会
膀胱癌诊断程序增加
膀胱癌是全球十大常见癌症之一，发病率和死亡率相当高，因此给医疗保健系统带来了沉重的负担。用于诊断膀胱癌的几种技术包括超声波、计算机断层扫描 (CT) 扫描、磁共振成像 (MRI)，有时还包括正电子发射断层扫描 (PET)。
治疗生长速度缓慢的膀胱癌可能需要监测。恶性肿瘤的化疗有时与放射疗法和干细胞移植相结合。人们更喜欢治疗和诊断。此外，癌症发病率的上升也是诊断产品获批增加的一个推动因素。
克制/挑战
膀胱癌治疗药物和疗法的副作用
化疗 (chemo) 使用通常通过静脉 (IV) 或口服的抗癌药物。这些药物进入血液并到达身体的几乎所有部位。然而，许多化疗药物无法进入膀胱并到达肿瘤细胞。卡介苗 (BCG) 是治疗早期膀胱癌最常见的膀胱内免疫疗法。BCG 是一种与引起结核病 (TB) 的细菌有关的细菌，但通常不会引起严重疾病。当 BCG 以液体形式通过导管进入膀胱时，它有助于“开启”那里的免疫系统细胞，然后攻击膀胱癌细胞。
化疗药物会引起副作用。这些取决于药物的类型和剂量以及治疗持续时间。常见的副作用包括脱发、口腔溃疡、食欲不振、恶心和呕吐、腹泻、感染几率增加（由于白细胞太少）、容易瘀伤或出血（由于血小板太少）、疲劳（由于红细胞太少、代谢变化或其他因素）。一些化疗药物还会引起其他不太常见的副作用。例如，顺铂和卡铂也会导致肾脏损伤和听力丧失。有时，可能需要减少药物剂量，或者可能需要延迟或停止治疗以防止效果恶化。因此，膀胱癌治疗药物和疗法的副作用可能会抑制北美膀胱癌诊断市场的增长。
COVID-19 疫情对北美膀胱癌诊断市场的影响
COVID-19 对北美膀胱癌诊断市场产生了负面影响。封锁限制导致各种挑战的出现，例如医院就诊人数减少和治疗程序延迟。
COVID-19 疫情在一定程度上对市场产生了负面影响。然而，政府支持的增加和成像技术的进步预计将为市场增长提供丰厚的机会。此外，市场参与者之间日益增多的伙伴关系、收购和协作预计将进一步推动市场增长。此外，自 COVID-19 疫情后市场开放以来，增长一直很高，预计该行业将有相当大的增长。市场参与者正在开展多项活动，以改进用于早期发现膀胱癌的成像技术。通过这种方式，这些公司将为市场带来进步和创新。
最新动态
- 2020 年 5 月，F. Hoffmann-La Roche Ltd 正式收购 Stratos Genomics。通过此次收购，该公司还将致力于开发用于诊断的基于 DNA 的测序。这增强了公司的医疗诊断部门，从而为公司带来了更多收入。
- 2023年1月，赛默飞世尔科技公司宣布已完成收购北美专业诊断领域领导者The Binding Site Group的协议。此次收购将有助于专业诊断部门的发展。
北美膀胱癌诊断市场范围
北美膀胱癌诊断市场根据检测类型、阶段、癌症类型、最终用户和分销渠道分为五个显著的细分市场。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
测试类型
- 膀胱镜检查
- 尿液实验室检查
- 活检
- 影像学检查
- 其他的
根据测试类型，市场分为膀胱镜检查、尿液实验室测试、活检、影像学测试等。
阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
根据阶段，市场分为第一阶段、第二阶段、第三阶段和第四阶段。
癌症类型
- 膀胱移行细胞癌
- 鳞状细胞膀胱癌
- 其他癌症类型
根据癌症类型，市场分为移行细胞膀胱癌、鳞状细胞膀胱癌和其他癌症类型。
最终用户
- 医院
- 诊断影像中心
- 癌症研究机构
- 独立诊断实验室
- 相关实验室
根据最终用户，市场分为医院、诊断成像中心、癌症研究机构、独立诊断实验室和相关实验室。
分销渠道
- 直接招标
- 零售销售
根据分销渠道，市场分为直接招标和零售。
北美膀胱癌诊断市场区域分析/见解
对北美膀胱癌诊断市场进行了分析，并按国家、测试类型、阶段、癌症类型、最终用户和分销渠道提供了市场规模洞察和趋势。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
预计美国将以最大的市场份额占据市场主导地位。这一份额归因于 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV 和 Bio-Rad Laboratories, Inc. 等主要市场参与者的存在。预计在预测期内，膀胱癌患病率的上升和成像技术的改进将推动该地区市场的增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和北美膀胱癌诊断市场份额分析
北美膀胱癌诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
北美膀胱癌诊断市场的一些主要市场参与者包括 F. Hoffmann-La Roche Ltd、Merck KGaA、Thermo Fisher Scientific Inc.、Koninklijke Philips NV、Bio-Rad Laboratories, Inc.、Agilent Technologies, Inc.、FUJIFILM Corporation、CANON MEDICAL SYSTEMS CORPORATION、Siemens Healthcare GmbH、BD、Illumina, Inc. Neusoft Corporation、Abbott、General Electric Company、Hologic Inc.、QIAGEN、Cepheid、Ambu A/S、Time Medical Holding 和 MinFound Medical Systems Co. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TEST TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT
6 REGULATORY FRAMEWORK
6.1 REGULATORY SCENARIO IN THE U.S
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS
7.3.3 INCREASE IN THE GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES
8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 CYSTOSCOPY
8.3 URINE LAB TEST
8.3.1 URINE CYTOLOGY
8.3.2 URINALYSIS
8.3.3 URINE TUMOR MARKER TEST
8.3.4 URINE CULTURE
8.3.5 OTHERS
8.4 BIOPSY
8.5 IMAGING TEST
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.5.3 ULTRASOUND
8.5.4 INTRAVENOUS PYELOGRAM (IVP)
8.6 OTHERS
9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES
9.1 OVERVIEW
9.2 STAGE IV
9.3 STAGE III
9.4 STAGE II
9.5 STAGE I
10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 TRANSITIONAL CELL BLADDER CANCER
10.3 SQUAMOUS CELL BLADDER CANCER
10.4 OTHER CANCER TYPES
11 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 DIAGNOSTIC IMAGING CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES
11.6 ASSOCIATED LABS
12 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
16.1 F. HOFFMANN- LA ROCHE LTD
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 MERCK KGAA
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 THERMO FISHER SCIENTIFIC INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 KONINLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 BIO-RAD LABORATORIES, INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SNAPSHOT
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AGILENT TECHNOLOGIES, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 AMBU A/S
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BD
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CANON MEDICAL SYSTEMS CORPORATION
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 FUJIFILM CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 GENERAL ELECTRIC COMPANY
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 HOLOGIC INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 ILLUMINA INC
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MINFOUND MEDICAL SYSTEMS CO.,
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 NEUSOFT CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 COMPANY SNAPSHOT
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 QIAGEN
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 SIEMENS HEALTHCARE GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 35 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.S. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 U.S. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 39 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 40 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 42 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 CANADA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 CANADA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 46 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 47 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MEXICO URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 MEXICO IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 53 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 54 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 55 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 15 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022
FIGURE 19 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 39 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
